Aprea Therapeutics (NASDAQ:APRE) Shares Up 2.8% – Here’s What Happened

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s stock price shot up 2.8% during trading on Friday . The stock traded as high as $1.70 and last traded at $1.65. 41,193 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 51,390 shares. The stock had previously closed at $1.60.

Analyst Ratings Changes

Separately, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Aprea Therapeutics in a report on Thursday, June 26th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $15.50.

Aprea Therapeutics Trading Up 2.8%

The business’s 50-day moving average price is $1.73 and its 200-day moving average price is $1.97. The stock has a market cap of $9.59 million, a PE ratio of -0.71 and a beta of 1.29.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.24. Aprea Therapeutics had a negative net margin of 1,645.01% and a negative return on equity of 78.90%. The firm had revenue of $0.12 million for the quarter. As a group, analysts predict that Aprea Therapeutics, Inc. will post -2.55 earnings per share for the current year.

Institutional Trading of Aprea Therapeutics

Several large investors have recently bought and sold shares of the stock. Stonepine Capital Management LLC grew its position in Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in Aprea Therapeutics during the 4th quarter worth approximately $43,000. Finally, LPL Financial LLC purchased a new stake in Aprea Therapeutics during the 4th quarter worth approximately $53,000. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.